GSS Stock Overview
Genetic Signatures Limited operates as a molecular diagnostic (MDx) company in Australia, the Asia Pacific, the Americas, Europe, the Middle East, Israel, and Africa.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Genetic Signatures Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.72 |
| 52 Week High | AU$0.75 |
| 52 Week Low | AU$0.38 |
| Beta | 0.15 |
| 1 Month Change | 2.86% |
| 3 Month Change | 44.00% |
| 1 Year Change | 7.46% |
| 3 Year Change | -39.50% |
| 5 Year Change | -34.84% |
| Change since IPO | 48.45% |
Recent News & Updates
Recent updates
After Leaping 42% Genetic Signatures Limited (ASX:GSS) Shares Are Not Flying Under The Radar
Mar 08
A Look At The Fair Value Of Genetic Signatures Limited (ASX:GSS)
Nov 14Genetic Signatures Limited (ASX:GSS) Investors Are Less Pessimistic Than Expected
Oct 10One Genetic Signatures Limited (ASX:GSS) Analyst Just Made A Major Cut To Next Year's Estimates
Jun 29Genetic Signatures (ASX:GSS) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Feb 28AU$3.20: That's What Analysts Think Genetic Signatures Limited (ASX:GSS) Is Worth After Its Latest Results
Feb 25What Kind Of Shareholders Hold The Majority In Genetic Signatures Limited's (ASX:GSS) Shares?
Feb 07
What Does Genetic Signatures' (ASX:GSS) CEO Pay Reveal?
Jan 17Genetic Signatures' (ASX:GSS) Wonderful 522% Share Price Increase Shows How Capitalism Can Build Wealth
Dec 27Genetic Signatures (ASX:GSS) Is In A Strong Position To Grow Its Business
Dec 06Shareholder Returns
| GSS | AU Life Sciences | AU Market | |
|---|---|---|---|
| 7D | 3.6% | -1.7% | 0.5% |
| 1Y | 7.5% | -13.2% | 6.2% |
Return vs Industry: GSS exceeded the Australian Life Sciences industry which returned -13.2% over the past year.
Return vs Market: GSS exceeded the Australian Market which returned 6.2% over the past year.
Price Volatility
| GSS volatility | |
|---|---|
| GSS Average Weekly Movement | 7.2% |
| Life Sciences Industry Average Movement | 10.6% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in AU Market | 17.6% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: GSS's share price has been volatile over the past 3 months.
Volatility Over Time: GSS's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | John Melki | www.geneticsignatures.com |
Genetic Signatures Limited operates as a molecular diagnostic (MDx) company in Australia, the Asia Pacific, the Americas, Europe, the Middle East, Israel, and Africa. It designs and manufactures a suite of real-time polymerase chain reaction-based products for detection of infectious diseases under the EasyScreen brand name. The company also provides MDx 3Base platform technology that enables hospital and pathology laboratories to screen for a range of infectious pathogens.
Genetic Signatures Limited Fundamentals Summary
| GSS fundamental statistics | |
|---|---|
| Market cap | AU$139.86m |
| Earnings (TTM) | -AU$18.04m |
| Revenue (TTM) | AU$15.99m |
8.4x
P/S Ratio-7.4x
P/E RatioIs GSS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GSS income statement (TTM) | |
|---|---|
| Revenue | AU$15.99m |
| Cost of Revenue | AU$9.79m |
| Gross Profit | AU$6.20m |
| Other Expenses | AU$24.24m |
| Earnings | -AU$18.04m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.097 |
| Gross Margin | 38.79% |
| Net Profit Margin | -112.83% |
| Debt/Equity Ratio | 0% |
How did GSS perform over the long term?
See historical performance and comparison